Vistagen — Fiscal Year 2027 Second Quarter Earnings Summary

Vistagen Therapeutics reported a net loss of $10.7 million for the second quarter of fiscal year 2027, ending September 30, 2026, with cash and marketable securities totaling $20.0 million. The company received constructive feedback from the FDA regarding its Phase 3 development plan for fasedienol in social anxiety disorder, which will now focus on overall treatment rather than just acute management. Preliminary data from the open-label extension of the PALISADE-4 study showed clinically relevant improvements in social anxiety over four months. Additionally, Vistagen appointed Douglas J. Williamson, MD, to its board and implemented cost-management initiatives to extend its operating runway into 2027.